KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Gains from Sales and Divestitures (2016 - 2019)

Exact Sciences (EXAS) has disclosed Gains from Sales and Divestitures for 10 consecutive years, with $3.5 million as the latest value for Q2 2019.

  • On a quarterly basis, Gains from Sales and Divestitures rose 271.43% to $3.5 million in Q2 2019 year-over-year; TTM through Jun 2019 was $3.5 million, a 271.43% increase, with the full-year FY2018 number at $1.3 million, up 12.85% from a year prior.
  • Gains from Sales and Divestitures was $3.5 million for Q2 2019 at Exact Sciences, up from $3.4 million in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $3.5 million in Q2 2019 to a low of $237061.0 in Q1 2015.
  • A 5-year average of $1.1 million and a median of $817710.0 in 2016 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: increased 11.84% in 2018, then surged 286.5% in 2019.
  • Exact Sciences' Gains from Sales and Divestitures stood at $578033.0 in 2015, then skyrocketed by 37.74% to $796168.0 in 2016, then soared by 42.21% to $1.1 million in 2017, then grew by 12.85% to $1.3 million in 2018, then soared by 174.4% to $3.5 million in 2019.
  • Per Business Quant, the three most recent readings for EXAS's Gains from Sales and Divestitures are $3.5 million (Q2 2019), $3.4 million (Q1 2019), and $1.3 million (Q4 2018).